AptamiR Therapeutics
PrivateLast Round
Seed
Sep 21, 2015
Total Funding Raised
$3M
Company Overview
AptamiR Therapeutics is a biotechnology company that develops microRNA-based oligonucleotide therapeutics to treat cardiometabolic disorders and ovarian cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AptamiR Therapeutics Comparables
Compare AptamiR Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Resalis Therapeutics | 86% | |
| Novo Nordisk | 73% | |
| miRecule, Inc. | 71% | |
AptamiR Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 21, 2015 |
AptamiR Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Austin Technology Incubator | Seed, Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2015
$3M raised with Austin Technology Incubator participating.
AptamiR Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AptamiR Therapeutics's valuation, stock price, and market status.